U.S.-based Kopernik Global Investors became a major shareholder of Kyorin Pharmaceutical, with its voting rights ratio exceeding 10%. As a result, Kyorin Pharmaceutical's shareholder composition changed.
On the 28th, Kyorin Pharmaceutical announced that U.S.-based Kopernik Global Investors had become a major shareholder of the company, holding more than 10% of its voting rights. Kopernik thereby gained status as a major shareholder of the company.
The article stated that Kopernik's total voting rights ratio before the change was 9.04%.